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Abstract The pediatric small vessel vasculitides reviewed
in this article are Henoch–Schönlein purpura (HSP) and the
anti-neutrophil cytoplasmic antibody-associated vasculiti-
des (AAV). The new classification criteria for HSP and
Wegener’s granulomatosis are now validated and will
facilitate the conduct of future epidemiological studies and
clinical trials. The clinical manifestations of small vessel
vasculitis in children are described, and current therapies
discussed. There is a lack of good clinical trial data on
which to base therapy for HSP. Similarly, data based on
randomized controlled trials (RCTs) for pediatric AAV are
lacking, although children with AAV are for the first time
now included in a RCT of mycophenolate mofetil versus
cyclophosphamide. Significant challenges remain in the
field of pediatric small vessel vasculitis, including the
development of validated disease outcome measures and
biomarkers to be used in clinical trials. Lastly, long-term
outcome data are lacking in survivors of pediatric small
vessel vasculitis.
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Introduction
This teaching article will review the main important
small vessel vasculitides affecting children. These include
Henoch–Schönlein purpura (HSP) and the anti-neutrophil
cytoplasmic antibody (ANCA)-associated vasculitides
(AAV) Wegener’s granulomatosis (WG), microscopic
polyangiitis (MPA), renal limited vasculitis, and Churg–
Strauss syndrome (CSS). Other small vessel vasculitides,
such as cutaneous leucytoclastic vasculitis, essential
cryoglobulinemic vasculitis, Behçet’ disease, Cogan’s
syndrome, and other rarer entities, will not be considered
here.
Henoch–Schönlein purpura
Definition
Henoch–Schönlein purpura (HSP) is defined as a vascu-
litis with immunoglobulin (Ig)A-dominant immune
deposits affecting small vessels and typically involving
the skin, gut, and glomeruli and associated with
arthralgias or arthritis [1]. It is the most common
childhood primary systemic vasculitis [2]. The modifica-
tions of the classification criteria defining HSP described by
Ozen et al. in 2005 [3] have recently been accepted
following a formal validation study [4]. According to the
new EULAR/PRINTO/PRES definition, a patient is classi-
fied as having HSP in the presence of purpura (commonly
palpable) or petechiae with lower limb predominance
(mandatory criterion) plus one of the four following
criteria:
1. abdominal pain;
2. histopathology showing typical leukocytoclastic vascu-
litis with predominant IgA deposit or proliferative
glomerulonephritis with predominant IgA deposit;
3. arthritis or arthralgia;
4. renal involvement (proteinuria or hematuria or presence
of red blood cell casts).
P. Brogan (*): D. Eleftheriou
Department of Rheumatology, Institute of Child Health,
30 Guilford St,
London WC1N1EH, UK
e-mail: p.brogan@ich.ucl.ac.uk
M. Dillon
Department of Nephro-urology, Institute of Child Health,
30 Guilford St,
London WC1N1EH, UK
Pediatr Nephrol (2010) 25:1025–1035
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demonstration of IgA is required at biopsy. This new
definition provides sensitivity and specificity for the
classification of HSP (using other forms of vasculitis as
controls) of 100 and 87%, respectively [4].
Manifestations
Henoch–Schönlein purpura typically affects children be-
tween the age of 3 and 10 years [5]. Gardner-Medwin et al.
reported a large population-based survey (1.1 million
children aged <17 years) from a multi-ethnic region of the
UK [2]. The annual incidence was estimated to be 20.4 per
100,000 children in the UK, with a greater incidence in
children from the Indian subcontinent (24 per 100,000)
compared with White Caucasians (17.8 per 100,000) and
Blacks (predominantly Afro-Caribbean: 6.2 per 100,000)
[2]. Other epidemiological studies from the Netherlands
and the Czech Republic place the incidence between 6.1
and 10.2 per 100,000 children, respectively, possibly
reflecting differences in ethnicity and/or methodological
differences in data collection in these studies [6, 7]. Yang et
al. reported that HSP has an annual incidence of 12.9 per
100,000 children in Taiwan [8]. In addition, a wide variety
of infectious agents have been reported as potential triggers
of HSP [9]. Several polymorphisms relating to disease
susceptibility, severity, and/or risk of renal involvement
have recently been described [10, 11]. Many of these
polymorphisms relate to cytokines or cell adhesion mole-
cules involved in the modulation of inflammatory responses
and endothelial cell activation [9]. On the whole, studies of
this nature have been hampered by relatively small patient
numbers; consequently, they lack the power to be definitive
or necessarily applicable to all racial groups.
Skin involvement is typically with purpura which is
generally symmetrical, affecting the lower limbs and
buttocks in the majority of cases; the upper extremities
are involved less frequently. The abdomen, chest, and face
are generally unaffected. New crops of purpura may
develop for several months after disease onset, though
these generally fade with time. Lesions can be induced by
mild trauma. Angioedema and urticaria can also occur.
Around two-thirds of children have joint manifestations
at presentation. The knees and ankles are most frequently
involved. Symptoms, which take the form of pain, swelling,
and decreased range of movement, tend to be fleeting and
resolve without the development of permanent damage.
Three-quarters of children develop abdominal symptoms
ranging from mild colic to severe pain with ileus and
vomiting. Hematemesis and melena are sometimes ob-
served. Other complications include intestinal perforation
and intussusception. The latter may be difficult to distin-
guish from abdominal colic, and the incidence of intussus-
ception is significant enough to warrant exclusion by
ultrasound where suspected. Acute pancreatitis is also
described, although it is a rare complication [12].
Other organs less frequently involved include the central
nervous system (cerebral vasculitis), gonads (orchitis may
be confused with torsion of the testis), and the lungs
(pulmonary hemorrhage). Many cases follow an upper
respiratory tract infection, and the onset of the disorder may
be accompanied by systemic symptoms, including malaise
and mild pyrexia. Multiple organ involvement may be
present from the outset of the disease or, alternatively, an
evolving pattern may develop, with different organs
becoming involved at different time points over the course
of several days to several weeks. One complication worth
emphasizing for pediatric nephrologists is the rare but well-
recognized complication of ureteric obstruction [13].
Around one-third of children have signs and symptoms
for <14 days, one-third for 2–4 weeks, and one-third for
>4 weeks [14]. Recurrence of symptoms occurs in around
one-third of cases, generally within 4 months of resolution
of the original symptoms. Recurrences are more frequent in
those patients with renal involvement [14].
Reports of HSP nephritis indicate that between 20–61%
of cases are affected with this complication [15, 16]. Renal
involvement is normally manifest between a few days and a
few weeks after first clinical presentation, but it can occur
up to 2 months or (rarely) more following presentation.
Patients with bloody stools appear to have an increased risk
of renal disease [14]. Renal involvement can present with
varying degrees of severity, including isolated microscopic
hematuria, proteinuria with microscopic or macroscopic
hematuria, acute nephritic syndrome (hematuria with at
least two of hypertension, raised plasma creatinine and
oliguria), nephrotic syndrome (usually with microscopic
hematuria), or a mixed nephritic–nephrotic picture.
Diagnosis
Diagnosis is usually straightforward clinically, with the
typical skin rash (predominantly lower limb purpura) being
the main clue, often accompanied by abdominal pain and
arthralgia or overt arthritis. No single laboratory test is
available for the diagnosis of HSP. Immunological inves-
tigations including complement levels and anti-nuclear anti-
bodies are normal. The IgA level is elevated in approximately
one-half of children, and a small number exhibit ANCA
positivity [17]. Coagulation studies are normal (although
factor XIII may be low; see below), and platelet numbers are
normal or occasionally increased. Where significant nephritis
is present at presentation, renal function and electrolytes may
be correspondingly abnormal.
Most children do not require a tissue (renal and/ or skin)
biopsy diagnosis, with the exception being children with
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ment. The skin lesion of HSP is that of a leukocytoclastic
vasculitis with perivascular accumulation of neutrophils
and mononuclear cells. The term leukocytoclasis refers to
the breakdown of white blood cells in lesional tissue and, in
particular, to the characteristic nuclear debris (“nuclear
dust”) that is observed; this breakdown is not specific for
HSP. Immunofluorescence studies reveal vascular deposi-
tion of IgA and C3 in the affected skin, although similar
changes may be observed in skin unaffected by the rash.
The cause of HSP is unknown, but it is likely that IgA has a
pivotal role in the pathogenesis of the disease, a hypothesis
supported by the almost universal deposition of IgA in
lesional vascular tissue. Galactose deficiency of O-linked
glycans in the hinge region of IgA1 has recently been
reported in adults with IgA nephropathy and children with
HSP [18]. Of note, however, it is possible to fail to detect
IgA deposition in cutaneous vascular tissue in some cases
of HSP, especially if the biopsy was obtained from the
middle of a lesion where the presence of proteolytic
enzymes can result in negative staining for IgA [19].
It is recognized that disease activity may be linked to a
rapid decline in factor XIII, particularly in patients with
severe abdominal involvement and, in some cases, before
the appearance of the classical skin rash [20–22]. There
have been anecdotal reports of factor XIII replacement to
treat severe abdominal symptoms [21]. The levels of factor
XIII also declines prior to the recurrence of HSP.
The renal lesion of HSP nephritis is characteristically a
focal and segmental proliferative glomerulonephritis. Se-
vere cases with rapidly progressive glomerulonephritis
usually demonstrate a high percentage of crescentic
glomerular changes on renal biopsy. Indications for
diagnostic renal biopsy in children with HSP are [23]:
& nephritic/nephrotic presentation (urgent);
& raised creatinine, hypertension or oliguria (urgent);
& heavy proteinuria (urine albumin/urine creatinine ratio
persistently >100 mg/mmol) on an early morning urine
sample at 4 weeks; serum albumin not necessarily in the
nephrotic range;
& persistent proteinuria (not declining) after 4 weeks;
& consider biopsy for persistent impaired renal function
[glomerular filtration rate (GFR) <80 ml/min/1.73 m
2].
The differential diagnosis of HSP includes sepsis (partic-
ularly meningococcal septicaemia), other systemic vasculiti-
des [systemic lupus erythematosus (SLE), polyarteritis
nodosa (PAN), WG, MPA, hypersensitivity vasculitis, and
cutaneous leukocytoclastic vasculitis], all of which can
present with similar clinical features [23]. Isolated cutaneous
leukocyclastic vasculitis does not typically present with a
history of a hypersensitivity reaction to drugs or infections
and hence should be differentiated clinically from true
hypersensitivity vasculitis [24]. Cutaneous leukocytoclastic
vasculitis can occur with arthralgia and thus mimic HSP, but
it is not associated with the other systemic features of HSP,
such as renal involvement. Thus, the diagnosis of true
cutaneous leukocytoclastic vasculitis is one of exclusion
after screening for features of systemic features [24].
Familial Mediterranean fever can also mimic or occur in
association with HSP in areas where this is endemic [25, 26].
Treatment
The large majority of cases of HSP require symptomatic treat-
ment only. Arthropathy is managed with rest and analgesia.
The management of HSP nephritis has recently been
reviewed by Zaffanello and Fanos [27]. At the conclusion
of this extensive literature review, the authors emphasized
that currently prescribed treatments for HSP nephritis are
not adequately guided by evidence obtained in robust
randomized placebo-controlled trials with outcome markers
related to the progression to end stage renal disease. The
following is a more detailed discussion.
Treatment to prevent renal disease Various treatment
strategies and strategies with the aim of preventing disease
complications, such as renal disease, have been reported to
have variable effects. The efficacy of corticosteroids to
prevent complications such as abdominal pain is still debated
[28, 29]. Chartapisak et al. recently systematically reviewed
all published randomized controlled trials (RCTs) for the
prevention or treatment of renal involvement in HSP [30].
Meta-analyses of four RCTs that evaluated prednisone
therapy at the presentation of HSP revealed that the risk of
renal involvement developing or persisting at 1, 3, 6, and 12
months with prednisone treatment was not significantly
different from that with placebo or no specific treatment. It is
therefore becoming clearer that prophylactic corticosteroid
does not prevent the onset of HSP nephritis. That said, there
could still be a role for the early use of corticosteroids in
patients with severe extrarenal symptoms and in those with
renal involvement, as suggested by the findings of a study
performed by Ronkainen et al. [29]. Prednisone treatment
(1 mg/kg/day for 2 weeks, with weaning over the subsequent
2 weeks) was effective in reducing the intensity of abdominal
pain and joint pain. Prednisone did not prevent the develop-
ment of renal symptoms, but it was effective in treating them
if present; renal symptoms resolved in 61% of the prednisone
patients after treatment, compared with 34% of the placebo
patients, although it should be noted that the renal involve-
ment in the patients in this study was relatively mild [29].
Treatment of rapidly progressive glomerulonephritis There
are good data indicating that crescents in >50% of glomeruli
and nephrotic range proteinuria carry an unfavorable
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intervention. Unfortunately, to date, there is only one
published RCT that has evaluated the benefit of treatment,
showing no difference in outcome using cyclophosphamide
versus supportive therapy alone [31]. However, this study
did not examine combined therapy, i.e. cyclophosphamide
and steroid, which is a regimen used in most other severe
small vessel vasculitides (see below). For patients with
rapidly progressive glomerulonephritis (RPGN) with cres-
centic change on biopsy, uncontrolled data suggest that
treatment may comprise aggressive therapy with corticoste-
roid, cyclophosphamide and, possibly, plasma exchange [27],
as for other causes of crescentic nephritis. Other therapies,
such as cyclosporine A, azathioprine, and cyclophospha-
mide, have been reported by some authors to be effective
[27]. As HSP is probably the commonest cause of rapidly
progressive glomerulonephritis in childhood, more aggres-
sive therapeutic approaches have been employed in some
cases. Shenoy et al. reported on 14 children with severe HSP
nephritis treated successfully with plasma exchange alone
[32]. These treatment options, whilst potentially important in
select cases, are not yet supported by the outcomes of RCTs.
Treatment of HSP nephritis that is not rapidly progressive Such
patients may exhibit the following features: less than 50%
crescents on renal biopsy, sub-optimal GFR, and heavy
proteinuria which is not necessarily in the nephrotic range
[23]. There are no outcomes from robust clinical trials to
guide the therapy of this type of presentation. Many would
advocate corticosteroids. Others advocate the addition of
cyclophosphamide to corticosteroids in HSP nephritis in
which biopsy shows diffuse proliferative lesions or sclerosis,
but with <50% crescentic change, in patients who have
ongoing heavy proteinuria. A typical regimen would
comprise 8 weeks of oral cyclophosphamide (2 mg/kg/day)
with intravenous pulsed methylprednisolone [33], followed
by daily prednisolone, and converting to alternate day
prednisolone and azathioprine for a total of 12 months [23].
Published evidence for the efficacy of this approach is
lacking, but this may be a reasonable option bearing in
mind the adverse prognosis of children with HSP who
have a nephritic/nephrotic phenotype, particularly if
therapy is delayed. In patients with >6 months duration
of proteinuria an angiotensin converting enzyme (ACE)
inhibitor may be indicated to limit secondary glomerular
injury, although again the evidence to support this therapy
is lacking [27].
Outcome
The majority of children with HSP make a full and
uneventful recovery with no evidence of ongoing signif-
icant renal disease. Renal involvement is the most serious
long-term complication of HSP. A study of the long-term
outcome of 78 subjects who had Henoch–Schönlein
nephritis during childhood (mean of 23.4 years after
onset) demonstrated overall that initial findings on renal
biopsy correlated well with outcome but that they had a
poor predictive value in individual patients [34]. Of the
patients who had nephritic, nephrotic, or nephritic/ne-
phrotic syndromes at onset, 44% had hypertension or
impaired renal function, whereas 82% of those who
presented with hematuria (with or without proteinuria)
were normal [34]. Seven patients deteriorated clinically
years after apparent complete clinical recovery. Of the 44
full-term pregnancies, 16 were complicated by proteinuria
and/or hypertension, even in the absence of active renal
disease [34].
Narchi systematically reviewed all published literature
on long-term renal impairment in children with HSP
[35]. Twelve studies with 1133 children were reviewed.
Renal involvement occurred in 34% of children; 80% had
isolated hematuria and/or proteinuria, while 20% had
acute nephritis or nephrotic syndrome [35]. Renal compli-
cations, if they did occur, developed early—by 4 weeks in
85% of children and by 6 months in nearly all children
[35]. Persistent renal involvement (hypertension, reduced
renal function, nephrotic or nephritic syndrome) occurred
in 1.8% of children overall, but the incidence varied with
the severity of the kidney disease at presentation, occur-
ring in 5% of children with isolated hematuria and/or
proteinuria but in 20% who had acute nephritis and/or
nephrotic syndrome in the acute phase [35]. Children with
significant renal impairment at presentation and/or persis-
tent proteinuria should undergo regular assessment of their
GFR, such as 1, 3, and 5 years after the acute episode of
HSP [23]. Some instances of hypertension have been
reported many years after the normalization of renal
function and urinalysis [36]. An increased incidence of
pre-eclampsia has also been reported. Interestingly, in
children who underwent repeat renal biopsies, the majority
of children with HSP still had IgA years later [37], which
could partly explain the later renal morbidity sometimes
described.
Thus, it is clear that robust clinical trials for the
treatment of moderate and severe HSP nephritis are
urgently required.
Lastly, it is recognized that HSP can occur in
renal allografts [38]. True recurrence should, however,
be differentiated from IgA deposits that are sometimes
seen in renal transplants in patients who did not have
HSP or IgA nephropathy [14]. One worrying suggestion
is that recurrence rates may be higher for living
donor transplants, although data are limited in this
area [39].
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vasculitides
The AAV are Wegener’s granulomatosis, microscopic
polyangiitis, Churg–Strauss syndrome, and so-called renal
limited vasculitis (previously referred to as idiopathic
crescentic glomerulonephritis) [40]. Patients with renal
limited vasculitis present with pauci-immune necrotizing
crescentic glomerulonephritis (NCGN) without extrarenal
manifestations of systemic vasculitis. Most of these patients
have ANCA directed against myeloperoxidase (MPO-
ANCA); hence, the condition is considered to be a form of
MPA limited to the kidney. Although rare, the AAV do occur
inchildhood,althoughCSSisextremelyrare inchildren[41].
The most accepted model of pathogenesis proposes that
ANCA activate cytokine-primed neutrophils, leading to
bystander damage of endothelial cells and an escalation of
inflammation with recruitment of mononuclear cells [42].
However, other concomitant exogenous factors and genetic
susceptibility appear to be necessary for disease expression
as well. The AAV are considered individually in the
following sections.
Wegener’s granulomatosis
Definition
Wegener’s granulomatosis is defined according to the
Chapel–Hill criteria as granulomatous inflammation involv-
ing the respiratory tract, with necrotizing vasculitis affect-
ing small to medium-sized vessels (e.g. capillaries, venules,
arterioles, and arteries); necrotizing glomerulonephritis is
common [1].
The recently modified classification definition for WG
requires the presence of three of the following six criteria:
& renal involvement (proteinuria or hematuria or red
blood cell casts);
& positive histopathology (granulomatous inflammation
within the wall of an artery or in the perivascular or
extravascular area);
& upper airway involvement (nasal discharge or septum
perforation, sinus inflammation);
& laryngotracheobronchial involvement (subglottic, tra-
cheal or bronchial stenosis);
& pulmonary involvement [chest X-ray or computed
tomography (CT)];
& ANCA positivity [by immunofluorescence, or by
enzyme-linked immunosorbent assay (ELISA) protein-
ase 3 (PR3)-ANCA or MPO-ANCA.
The sensitivity and specificity of the new EULAR/
PRINTO/PRES criteria are 93 and 99%, respectively, for
the classification of WG as distinct from other forms of
vasculitis in the pediatric population ([43], Brogan et al.,
submitted).
Definition of other AAV
Microscopic polyangiitis (formerly microscopic polyarter-
itis) differs from classic PAN by the presence of extensive
glomerular involvement. Microscopic polyangiitis may be
defined as necrotizing vasculitis, with few or no immune
deposits, affecting small vessels (i.e. capillaries, venules, or
arterioles); necrotizing arteritis involving small and
medium-sized arteries may be present. In addition, necro-
tizing glomerulonephritis is very common, and pulmonary
capillaritis often occurs [1]. Clinically, MPA can be difficult
to distinguish from WG and often presents with rapidly
progressive pauci-immune glomerulonephritis [44] in asso-
ciation with perinuclear ANCA (pANCA) positivity [1].
Renal limited AAV describes those patients with rapidly
progressive glomerulonephritis, often with ANCA positiv-
ity (usually MPO-ANCA) but without other organ involve-
ment. This condition probably represents a forme fruste
MPA.
Churg–Strauss syndrome was defined in the Chapel–Hill
Consensus as an eosinophil-rich and granulomatous inflam-
mation involving the respiratory tract and necrotizing
vasculitis affecting small to medium-sized vessels; there is
an association with asthma and eosinophilia [1].
Manifestations of WG
Wegener’s granulomatosis typically affects the upper and
lower respiratory tract and is associated with glomerulone-
phritis, although the disease can affect any organ system in
the body [45]. The typical pathological process is granulo-
matous inflammation with or without necrotizing small
vessel vasculitis. From a clinical perspective, it may be
useful to think of WG as having two forms: (1) a
predominantly granulomatous form with mainly localized
disease with a chronic course, and (2) a florid, acute small
vessel vasculitic form characterized by severe pulmonary
hemorrhage and/or rapidly progressive vasculitis or other
severe vasculitic manifestation (see below). These two
broad presentations may coexist or present sequentially in
individual patients.
Symptoms and signs of upper respiratory tract involve-
ment include epistaxis, otalgia, and hearing loss (conduc-
tive and sensorineural) [45]. Nasal septal involvement with
cartilaginous collapse results in the characteristic saddle
nose deformity, although this may not be present at initial
presentation. Inspection inside the nares using an auriscope
may reveal inflammation with bleeding and crusting.
Chronic sinusitis may be observed. Glottic and subglottic
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result from granulomatous inflammation. Lower respiratory
tract manifestations also include granulomatous pulmonary
nodules with or without central cavitation (Fig. 1) as well as
pulmonary hemorrhages that can be relatively asymptom-
atic but which result in evanescent pulmonary shadows on
chest X-ray or catastrophic pulmonary hemorrhage from
pulmonary capillaritis associated with respiratory failure
and high mortality (Fig. 2).
The typical renal lesion is a focal segmental necrotizing
glomerulonephritis, with pauci-immune crescentic glomer-
ular changes (Fig. 3). Clinical manifestations relating to this
lesion include hypertension, significant proteinuria, nephrit-
ic and nephrotic syndrome and, ultimately, the protean
clinical manifestations of renal failure.
Other manifestations include orbital involvement with
granuloma (Fig. 4), retinal vasculitis, peripheral gangrene
with tissue loss, and vasculitis of the skin, gut, heart, central
nervous system and/or peripheral nerves (mononeuritis
multiplex), salivary glands, gonads, and breast. Non-
specificsymptoms,suchmalaise,fever,weightlossorgrowth
failure, arthralgia, and arthritis, are relatively common.
The frequency of different system involvement in one
published series of 17 children with WG was: respiratory,
87%; kidneys, 53%; sinuses, 35%; joints, 53%; eyes, 53%;
nervous system, 12%; skin, 53% [46]. Another pediatric
series of WG reported an even higher frequency of renal
involvement, with 22/25 patients having glomerulonephritis
at first presentation; only 1/11 patients who had renal
impairment in that series recovered renal function with
therapy [47]. Renal involvement in WG is recruited with
increasing age, which could partly account for the variation
in reported renal involvement in pediatric WG.
Manifestations of other AAV
Microscopic polyangiitis and renal limited AAV Micro-
scopic polyangiitis was initially considered to be a
“microscopic” form of polyarteritis nodosa, and the term
MPA was first used to distinguish this small vessel
vasculitis from classic PAN by the Chapel–Hill Consensus
in 1994 [1], although recognition of the clinical differences
between microscopic and classic PAN had been made long
before time by others. The typical clinical manifestations
Fig. 1 Pulmonary nodule in Wegener’s granulomatosis (WG).
Computed axial tomography scan of thorax revealing a pulmonary
nodule in a 12-year-old girl with WG with multi-systemic involve-
ment (see also Fig. 3)
Fig. 2 Diffuse alveolar hemorrhage in WG. Chest X-ray from a 14-
year-old girl with diffuse alveolar hemorrhage due to WG with high
titre PR3-anti-neutrophil cytoplasmic antibody (ANCA)
Fig. 3 Crescentic nephritis in WG. Focal segmental necrotizing
glomerulonephritis with fibrocellular crescent formation in a 12-year-
old girl with severe WG (same patient as shown in Fig. 1)
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hemorrhage. Other possible symptoms resemble those
encountered in PAN (see the review by Dillon et al. [43]).
In adults, 75–80% of patients have pANCA/MPO-ANCA.
The pathogenicity of MPO-ANCA has been established in
animal models [48] and in at least two cases of transpla-
cental transmission in humans resulting in affected neonates
[49, 50]. Renal limited forms have been described in
children and adults.
Churg–Strauss Syndrome In a recent review of 33 cases of
childhood CSS, all patients had significant eosinophilia and
asthma [41]. Furthermore, histological evidence of eosino-
philia and/or vasculitis was present in virtually all patients.
Anti-neutrophil cytoplasmic antibodies were found in only
25% of children with CSS.
Diagnosis
The diagnosis of AAV can be challenging and ANCA
undoubtedly play an important role. Methodological
improvements for the detection of ANCA have resulted in
increased sensitivity and specificity. Both indirect immu-
nofluorescence (IIF) and ELISA are used for routine
diagnostic purposes. Typically, WG is associated with a
cytoplasmic staining pattern of ANCA by IIF, and ELISA
reveals specificity against PR3 (PR3-ANCA). However,
pANCA with specificity directed against MPO (MPO-
ANCA) can also be found in patients with WG. Micro-
scopic polyangiitis and renal limited AAV are typically
associated with pANCA by IIF and with MPO-ANCA by
the ELISA.
Lastly, it should always be remembered that ANCA-
negative forms of WG, MPA, renal limited vasculitis, and
CSS are well described in children [41, 45].
Tissue diagnosis, in particular renal biopsy but also
biopsy of skin, nasal septum, or other tissue, can be
important diagnostically for diagnosing all of the AAV and
can help stage the disease for therapeutic decision-making.
While the diagnostic value of ANCA is without question
important, the value of ANCA for the longitudinal
monitoring of disease activity is probably unreliable in
many patients with WG [51]. The reasons for this
unreliability are not fully understood, but they are likely
to include methodological limitations of ANCA detection,
the partial dissociation of ANCA levels and disease activity
associated with the immunosuppressive therapy, and the as
yet undefined complexity in the exact role of ANCA in the
pathogenesis of WG [52].
Treatment of AAV
Renal morbidity and mortality are major concerns in the
treatment of AAV and, consequently, therapy aimed at
preserving renal function is a recurring theme when
determining the therapeutic options [52]. Treatment for
pediatric AAV is broadly similar to the approach used in
adults, with corticosteroids, cyclophosphamide (usually six
to ten intravenous doses of 500–1000 mg/m
2 per dose,
every three to four weeks; alternatively given orally at
2 mg/kg/day for 2–3 months), and plasma exchange
(particularly for pulmonary capillaritis and/or rapidly
Fig. 4 Orbital involvement in WG. a Magnetic resonance scan
revealing bilateral soft tissue lesions involving the superolateral
quadrants of both orbits in a 16-year-old girl with WG. b Orbital
biopsy specimen from the same patient revealing perivascular
granulomatous inflammation with fibrinoid necrosis of the vessel wall
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drome”) routinely employed to induce remission [52–54].
Intravenous pulsed cyclophosphamide is increasingly gain-
ing favor over oral continuous cyclophosphamide in adults
because of its reduced cumulative dose and lower incidence
of neutropenic sepsis [55]. Consequently, it is being
increasingly used to treat children with AAV as well, albeit
without good pediatric evidence. This is followed by low
dose corticosteroids and azathioprine (1.5–3 mg/kg/day) to
maintain remission [56, 57]. Anti-platelet doses of aspirin
(1–5 mg/kg once a day) can also be considered empirically
on the basis of the increased risk of thrombosis associated
with the disease process [58]. Methotrexate may have a role
for inducing remission in patients with limited WG [59],
but it is less commonly used as an induction agent in
children with AAV. Co-trimoxazole is commonly added to
therapeutic programs for the treatment of WG, particularly
in those with upper respiratory tract involvement, serving
both as prophylaxis against opportunistic infection and as a
possible disease-modifying agent [60]. Recommendations
regarding the duration of maintenance therapy are based on
adult trial data which suggest that the strongest predictor of
relapse is the withdrawal of therapy. These data indicate
that maintenance therapy should be continued for several
years [52]. As a general therapeutic measure, prophylaxis
against osteoporosis, gastrointestinal ulceration, and infec-
tion (bacterial, protozoal, and fungal) are standard addi-
tional aspects of treatment for AAV [52].
As the use of cyclophosphamide contributes to morbid-
ity and mortality [52, 56], with infection playing a
prominent role [61], and disease relapses occur in 50% of
the patients with AAV as the drugs are reduced or
withdrawn, newer immunosuppressive agents and immu-
nomodulatory strategies are being explored in both adults
and children. Such treatments include mycophenolate
mofetil (MMF) and rituximab, which have already been
reported to be effective at inducing or maintaining
remission in adults with AAV [62, 63] and are currently
being evaluated in RCTs undertaken under the auspices of
the European Vasculitis Study Group (EUVAS) and other
groups worldwide. Of note is the EUVAS MYCYC trial
(UK and Europe), which is comparing induction therapy of
WG and MPA using cyclophosphamide (standard therapy)
versus MMF (experimental therapy). This is the first
EUVAS trial to include children as well as adults, and it
is actively recruiting patients under the age of 17 years in
the UK. At the time of writing this review, however, the rest
of Europe was not yet set up to recruit children. For a full
list of the past and present EUVAS trials for AVV, the
reader is directed to: http://www.vasculitis.org/.
Increasingly, biologic therapy is being used to treat
children with small vessel vasculitis, including AAVas well
as ANCA-negative vasculitides. Such agents include
rituximab, anti-tumor necrotizing factor-α (etanercept,
infliximab, and adalimumab), and anakinra (recombinant
interleukin 1 receptor antagonist) [64]. These therapies are
mainly reserved for those who have failed to respond to
standard treatment or for those patients for whom cumula-
tive cyclophosphamide and/or corticosteroid toxicity is of
particular concern [64]. Other novel therapies for AAV are
reviewed elsewhere [52, 56].
Specialist-localized treatment of the upper and lower
respiratory tract involvement of WG is beyond the scope of
this review. The reader is therefore directed to the report of
Hoffman et al. [65] and the recent report by White et al.
[66].
Outcome of AAV
The AAV still carry considerable disease-related morbidity
and mortality, particularly due to progressive renal failure
or aggressive respiratory involvement, and therapy-related
complications, such as sepsis.
The mortality for pediatric WG from one recent pediatric
series was 12% over a 17-year period of study inclusion
[46]. The largest pediatric series of patients with WG
reported 40% of cases with chronic renal impairment at
33 months of follow-up [47] despite therapy. Thus,
treatment has shifted WG from a disease associated with
high mortality in the first year [67] to that of a chronic
illness associated with relapsing course and high renal
morbidity during pediatric follow-up.
Mortality in pediatric patients with MPA during pediatric
follow-up has been reported to be between 0 and 14% [68,
69]. Two of seven children reported by Peco-Antic et al.
[70] progressed to end stage renal disease, one developed
chronic renal failure, and four normalized renal function.
The outcome of a study on a selected population of 31
Japanese children with necrotizing pauci-immune glomer-
ulonephritis and positive ANCA suggested a poor renal
prognosis despite therapy [69]. In that series, at 43 months
of follow-up 29% had developed end stage renal failure,
19.4% had reduced renal function, and only 48.4% had
normal renal function. Using these data, the authors
suggested that there was an overall renal survival of 75%
at 39 months, which is comparable to the poor renal
prognosis of MPA in adults [52].
For CSS in children, the most recent series quotes a
related mortality of 18%, all attributed to disease rather than
therapy [41].
Conclusion
Significant challenges remain to those concerned with the
management of small vessel vasculitides in children.
1032 Pediatr Nephrol (2010) 25:1025–1035Randomized controlled trials involving pediatric multicen-
ter collaboration are urgently required to guide therapy,
particularly for the AAV, but also for HSP. Future basic
science developments relating to the pathogenesis of
pediatric small vessel vasculitis (and other vasculitides),
including genetics, environmental factors, and host immu-
nological responses, are anticipated to improve our under-
standing of these diseases and provide new therapeutic
targets in the future. The development of validated disease
outcome measures and robust biomarkers of disease activity
will facilitate future clinical trials—and such developments
are currently underway. Lastly, long-term follow-up data
relating to such outcome variables as late mortality,
cardiovascular health, malignancy, and impact on education
are lacking for survivors of pediatric small vessel vasculitis.
Questions:
(answers appear at the end of the list of questions)
1. Regarding HSP, which of the following statements is
TRUE?
a. HSP never recurs in renal allografts.
b. IgA is always found on immunostaining of biopsies of
lesional tissue.
c. HSP rarely occurs after infections.
d. IgA may be elevated in sera.
2. Regarding Wegener’s granulomatosis in children,
which of the following is TRUE?
a. The diagnosis can be excluded in children if ANCA are
negative.
b. Serum ANCA levels correlate well with disease
activity.
c. Despite lack of RCT evidence, there is still a role for
plasma exchange in those with severe disease.
d. New therapies such as rituximab have replaced stan-
dard toxic therapies such as cyclophosphamide.
3. Regarding ANCA associated vasculitides, which of the
following is TRUE?
a. Plasma exchange has proven efficacy for the treatment
of WG in adults.
b. CSS in children only occurs as a result of therapy with
leukotriene inhibitors.
c. The majority of children with CSS are ANCA positive.
d. Etanercept has proven efficacy for the treatment of WG
in adults.
4. Regarding ANCA associated vasculitides, which of the
following statements is FALSE?
a. Wegener’s granulomatosis never affects the aorta.
b. Intravenous cyclophosphamide is preferable to oral
cyclophosphamide because it has a lower toxicity
profile.
c. Intravenous cyclophosphamide can be given to patients
with MESNA hypersensitivity.
d. Septrin (co-trimoxazole) may reduce relapses for
patients with WG and respiratory tract involvement.
5. Regarding the following clinical trials of small vessel
vasculitis, which of the following statements is TRUE?
a. Trials of novel therapies for small vessel vasculitis
should always be conducted in adults before children.
b. Lack of good RCT data precludes the use of rituximab
in the treatment of pediatric AAV.
c. RCT data suggest that early use of corticosteroids helps
prevent the onset of HSP nephritis.
d. The Birmingham vasculitis activity score can be
helpfully used in RCTs of therapy for small vessel
vasculitis.
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